SCHEMBL805507

SCHEMBL805507

CCCC(=O)N1CCN(C)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 4/20 0.50
GNAI1 P63096 4/20 0.50
TDP1 Q9NUW8 4/20 0.50
GNAO1 P09471 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
HTR1A P08908 1/20 0.50
CYP1A2 P05177 1/20 0.50
KMT2A Q03164 3/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 2/20 0.48
KDM4E B2RXH2 2/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
CYP3A4 P08684 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CHRNB2 P17787 1/20 0.47
CHRNA3 P32297 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10663507 0.91 L3MBTL1 (0.58) GNAI3GNAI1TDP1GNAO1L3MBTL1
SCHEMBL674671 0.91
SCHEMBL11240 0.87 L3MBTL1 (0.62) GNAI3GNAI1TDP1GNAO1L3MBTL1
SCHEMBL4548026 0.85 L3MBTL1 (0.71) GNAI3GNAI1TDP1GNAO1L3MBTL1
SCHEMBL13779924 0.84 HTT (0.54) GNAI3GNAI1GNAO1L3MBTL1KMT2A
SCHEMBL8972071 0.84 GNAI3 (0.71) GNAI3GNAI1TDP1GNAO1L3MBTL1
SCHEMBL8972364 0.84 GNAI3 (0.71) GNAI3GNAI1TDP1GNAO1L3MBTL1
SCHEMBL31632756 0.84 GNAI3 (0.71) GNAI3GNAI1TDP1GNAO1L3MBTL1
SCHEMBL8972105 0.84 GNAI3 (0.71) GNAI3GNAI1TDP1GNAO1L3MBTL1
SCHEMBL8972852 0.84 GNAI3 (0.71) GNAI3GNAI1TDP1GNAO1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116375715-B Compound serving as non-covalent BTK kinase inhibitor and biological application thereof 中国药科大学 2025-04-04 CN disclosed
EP-3816164-B9 ISOTHIAZOLO[5,4-D]PYRIMIDINE COMPOUND AS IRAK4 INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2024-07-10 EP disclosed
WO-2024026260-A1 SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS IRAK3 BINDERS CELGENE CORPORATION (US) 2024-02-01 WO disclosed
US-11725007-B2 Meta tyrosine derivatives as rho-kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2023-08-15 US disclosed
CN-116375715-A Compound serving as non-covalent BTK kinase inhibitor and biological application thereof 中国药科大学 2023-07-04 CN disclosed
CN-113195510-B Process for producing glucopyranosyl derivative and intermediate therefor 宜昌东阳光长江药业股份有限公司 2022-12-23 CN disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
EP-3728235-B1 SUBSTITUTED THIOPHENYLURACILS , THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS SYNGENTA CROP PROTECTION AG (CH) 2022-02-09 EP disclosed
EP-3831841-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T Global Inc. (US) 2021-06-09 EP disclosed
EP-3778571-A1 (2E,4E)-5-PHENYL-PENTA-2,4-DIEN-1-ONE DERIVATIVE Bioway, Inc. (KR) 2021-02-17 EP disclosed
US-20080139559-A1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) 2008-06-12 US disclosed
US-20080139597-A1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) 2008-06-12 US disclosed
US-20080139560-A1 Ion Channel Modulators SCION PHARMACEUTICALS, INC. 2008-06-12 US disclosed
US-20070191469-A1 Novel tetracyclic tetrahydrofuran derivatives JANSSEN-CILAG S.A. (ES) 2007-08-16 US disclosed
US-20070191469-A1 Novel tetracyclic tetrahydrofuran derivatives JANSSEN-CILAG S.A. (ES) 2007-08-16 US disclosed
US-20070149538-A1 Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors IRM LLC (BM) 2007-06-28 US disclosed
EP-1740574-B1 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES OTSUKA PHARMA CO LTD (JP) 2007-06-27 EP disclosed
WO-2007019674-A1 VIRAL POLYMERASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-22 WO disclosed
WO-2005097112-A2 ION CHANNEL MODULATORS WYETH (US) 2005-10-20 WO disclosed
US-20050070550-A1 Benzoimidazole compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070550-A1 Benzoimidazole compounds HRH4, HRH3, BRD4 GNAI3 771/4885GNAI1 1063/4885TDP1 4637/4885
US-20080139560-A1 Ion Channel Modulators CACNA1B, CACNA1C, TRPV1 GNAI3 724/4885GNAI1 673/4885TDP1 3756/4885
US-20070191469-A1 Novel tetracyclic tetrahydrofuran derivatives HTR2C, HTR2A, HTR1A GNAI3 464/4885GNAI1 203/4885TDP1 2025/4885
US-20080139597-A1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS KIT, PRKCH, PRKCE GNAI3 492/4885GNAI1 408/4885TDP1 2495/4885
US-11725007-B2 Meta tyrosine derivatives as rho-kinase inhibitors ROCK1, ROCK2, RHOA GNAI3 343/4885GNAI1 274/4885TDP1 1103/4885
US-20070149538-A1 Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors KIT, PRKCH, PRKCE GNAI3 492/4885GNAI1 408/4885TDP1 2495/4885
US-20080139559-A1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS KIT, PRKCH, PRKCE GNAI3 492/4885GNAI1 408/4885TDP1 2495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.